Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications
Movement Disorders · 2024
DOI: 10.1002/mds.29834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2024. Verfasst von Albert Stezin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India. Hauptthemen laut MEDLINE: Spinocerebellar Ataxias, Proteome. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Department of Science and Technology - Cognitive Science Research Initiative, Government of India, India Alliance DBT/Wellcome Trust Margdarshi Fellowship, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Background
Abnormalities in ataxin‐2 associated with spinocerebellar ataxia type 2 (SCA2) may lead to widespread disruptions in the proteome. This study was performed to identify dysregulated proteome in SCA2 and to explore its clinical‐radiological correlations.
Methods
Cerebrospinal fluid (CSF) samples from 21 genetically confirmed SCA2 were subjected to shotgun proteome analysis using mass spectrometry (MS) and tandem mass tag (TMT)‐based multiplexing. Proteins with at least 1.5‐fold change in abundance were identified. Their relative abundance was measured using parallel reaction monitoring (PRM) and correlated against disease‐related factors.
Results
Eleven proteins were significantly upregulated in SCA2. They belonged to the family of cell adhesion molecules and granins. Their fold changes showed significant clinical, genetic, and radiological correlations.
Conclusions
Significant dysregulation of CSF proteome is seen in SCA2. The dysregulated protein may have potential use in clinical evaluation of patients with SCA2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
- Clinical Neurosciences, Centre for Brain Research (CBR), Indian Institute of Science (IISc), Bangalore, India.
- Institute of Bioinformatics (IOB), Bangalore, India.
- Department of Clinical Psychology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
- Department of Neuroimaging and Interventional Neuroimaging, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
- Molecular Genetics Laboratory, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
ORCID-Profile: Sujas Bharadwaj, Vikram Holla, Shantala Hegde, Ravi Yadav, Pramod Kumar Pal
Förderung
- Department of Science and Technology - Cognitive Science Research Initiative, Government of India
- India Alliance DBT/Wellcome Trust Margdarshi Fellowship
- Department of Science and Technology, Ministry of Science and Technology, India
- Wellcome Trust DBT India Alliance
Zitieren
APA
Stezin, A., Sathe, G. J., Gajbhiye, A., Bharadwaj, S., Ghose, V., Bellad, A., Malo, P. K., Holla, V., Hegde, S., Bharath, R. D., Saini, J., Jain, S., Yadav, R., Pandey, A., & Pal, P. K. (2024). Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications. Movement Disorders. https://doi.org/10.1002/mds.29834
Vancouver
Stezin A, Sathe GJ, Gajbhiye A, Bharadwaj S, Ghose V, Bellad A, et al. Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications. Movement Disorders. 2024. doi:10.1002/mds.29834
BibTeX
@article{Stezin2024,
author = {Stezin, Albert and Sathe, Gajanan J and Gajbhiye, Akshada and Bharadwaj, Sujas and Ghose, Vivek and Bellad, Anikha and Malo, Palash Kumar and Holla, Vikram and Hegde, Shantala and Bharath, Rose Dawn and Saini, Jitender and Jain, Sanjeev and Yadav, Ravi and Pandey, Akhilesh and Pal, Pramod Kumar},
title = {Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications},
journal = {Movement Disorders},
year = {2024},
doi = {10.1002/mds.29834}
}
EUVIMED